200 results on '"Peg V"'
Search Results
2. Predictive and prognostic value of total tumor load in sentinel lymph nodes in breast cancer patients after neoadjuvant treatment using one-step nucleic acid amplification: the NEOVATTL study
3. The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience
4. Matrix Metalloproteinase-9 Expression Is Associated with the Absence of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
5. Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response
6. OSNA Total Tumor Load for the Prediction of Axillary Involvement in Breast Cancer Patients: Should We use Different Thresholds According to the Intrinsic Molecular Subtype? MOTTO Study
7. 165P EPclin, OncotypeDx and Prosigna in lobular breast cancer (ILC): Is there an association with Ki67?
8. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
9. Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay
10. 102P Long-term prediction of clinical outcomes by the 21-gene test in HR+ HER2- breast cancer patients with residual disease after neoadjuvant chemotherapy
11. 87P EPClin vs OncotypeDx in invasive lobular cancer (ILC)
12. The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets
13. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective
14. A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers
15. PD-L1 testing based on SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion
16. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists’ perspective
17. 65P Patient follow-up of NEOVATTL study
18. Dual regulation of Myc by Abl
19. 33P Immune analysis of lymph nodes in relation to the presence or absence of tumour infiltrating lymphocytes in triple negative breast cancers
20. Comparison of different doses of superparamagnetic iron oxide for sentinel node biopsy in breast cancer: the superparamagnetic iron oxide for sentinel node in breast cancer : (sunrise) randomized trial
21. Role of total tumour load of sentinel lymph node on survival in early breast cancer patients
22. Corrections to “Capturing intra-tumor genetic heterogeneity byde novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle”
23. Tumor-infiltrating lymphocytes density correlates with HER2 gene copy number but not with protein levels in HER2-positive breast cancer
24. Changes in Ki 67 expression after neoadjuvant therapy in HER2 positive breast cancer patients treated with trastuzumab and pertuzumab are independent predictors of response and prognosis
25. Breast and axillary conservative surgery after neoadjuvant treatment in HER 2 positive breast cancer patients: The time is now
26. Prognostic estimates of Ki-67 percentage drop after neoadjuvant chemotherapy (NAC) in luminal B (lumB) and triple negative breast cancer (TNBC)
27. The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience
28. Introducing the European Breast Cancer Collaborative
29. Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC)
30. Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC)
31. Abstract P4-07-04: PARP1/2 inhibition in a subset of triple negative breast cancer (TNBC) patient-derived tumor xenografts (PDX) identifies predictive biomarkers of response
32. Abstract P3-01-04: Improved sentinel lymph node detection with the use of superparamagnetic iron oxide tracer after neoadjuvant treatment in breast cancer patients
33. 440 (PB-073) - Tumor-infiltrating lymphocytes density correlates with HER2 gene copy number but not with protein levels in HER2-positive breast cancer
34. 350 (PB-145) - Changes in Ki 67 expression after neoadjuvant therapy in HER2 positive breast cancer patients treated with trastuzumab and pertuzumab are independent predictors of response and prognosis
35. 19 - Breast and axillary conservative surgery after neoadjuvant treatment in HER 2 positive breast cancer patients: The time is now
36. 218P - Prognostic estimates of Ki-67 percentage drop after neoadjuvant chemotherapy (NAC) in luminal B (lumB) and triple negative breast cancer (TNBC)
37. P188 - Introducing the European Breast Cancer Collaborative
38. P119 Recurrence Score® result by the 21-gene assay before and after systemic neoadjuvant chemotherapy in patients with HR+ HER2-breast cancer.
39. 306: Chemotherapy sensitizes p95HER2-positive breast cancers to trastuzumab
40. 1264P - Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC)
41. Abstract P1-01-29: Intraoperative molecular analysis of sentinel lymph node as a new predictor of axillary status in early breast cancer patients.
42. 676 HER3 Expression in Human Breast Carcinomas is Associated With Tumor Size and Estrogen Receptor Status
43. 684 Phosphorylation of EIF4E Enhances Survival and Growth Under Stress Conditions
44. A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers
45. 573 Sentinel Lymph Node Dissection in Breast Cancer Relapse After Previous Axillary Surgery
46. P3-07-45: Role of SPECT-CT in Detecting Sentinel Lymph Nodes in Patients with Ipsilateral Breast Cancer Recurrence and Previous Axillary Lymph Node Dissection.
47. P3-07-21: Sentinel Lymph Node Metastasis Are More Likely To Develop in Triple Positive Breast Cancer Patients without Compromising Disease Free Survival.
48. P5-11-12: Correlation of Ki67 Expression between Initial Biopsy and Surgical Specimen in Untreated Breast Cancer Patients. Does Menstrual Cycle Matter?
49. Expression of ErbB2 and ErbB3 in resected non-small cell lung cancer (NSCLC) patients (pts).
50. Abstract P1-01-05: Clinical Significance of Tumor Burden in the Sentinel Nodes after Neoadjuvant Therapy Differs from Sentinel Nodes in the Adjuvant Setting and This May Influence the Management of the Axilla
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.